"label","uuid:ID","instanceType","name","id","description","text"
"","26fcc56c-fb87-4e23-abfd-d0155dbb83b6","Objective","OBJ1","Objective_1","Main objective","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])."
"","b28cb200-70e1-49a9-9fae-b6f1e35788e0","Objective","OBJ2","Objective_2","Safety","To document the safety profile of the xanomeline TTS."
"","4ddaa988-835e-4ad9-b387-dfa927a644e3","Objective","OBJ3","Objective_3","Behaviour","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas."
"","acc9e3d3-b5ee-4da6-be3b-1055f60df7b6","Objective","OBJ4","Objective_4","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5)."
"","a2265bda-81ff-4bc4-a57c-2799e00382b3","Objective","OBJ5","Objective_5","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2)."
"","4e34fa16-33ae-4191-ac8d-95a00af32f0a","Objective","OBJ6","Objective_6","","To assess the treatment response as a function of Apo E genotype."
